دورية أكاديمية
Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
| العنوان: | Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen. |
|---|---|
| المؤلفون: | Valdivielso P; Lipid Unit, Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, Departamento de Medicina y Dermatología, Instituto de Investigación Biomédica (IBIMA-Plataforma BIONAND), Universidad de Málaga, Málaga, Spain. Electronic address: valdivielso@uma.es., Coca Prieto I; Lipid Unit, Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, Departamento de Medicina y Dermatología, Instituto de Investigación Biomédica (IBIMA-Plataforma BIONAND), Universidad de Málaga, Málaga, Spain. |
| المصدر: | Med (New York, N.Y.) [Med] 2024 Jun 14; Vol. 5 (6), pp. 493-494. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101769215 Publication Model: Print Cited Medium: Internet ISSN: 2666-6340 (Electronic) Linking ISSN: 26666340 NLM ISO Abbreviation: Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [New York] : Cell Press, [2020]- |
| مواضيع طبية MeSH: | Apolipoprotein C-III*/genetics , Apolipoprotein C-III*/blood , Hyperlipoproteinemia Type I*/genetics , Hyperlipoproteinemia Type I*/blood , Oligonucleotides*/pharmacology , Oligonucleotides*/therapeutic use , Triglycerides*/blood, Humans ; Oligonucleotides, Antisense/pharmacology ; Oligonucleotides, Antisense/therapeutic use ; Pancreatitis/genetics ; Benzimidazoles |
| مستخلص: | Reducing the synthesis of apoC-III reduces fasting triglycerides in individuals lacking lipoprotein lipase activity. Recently, Stroes et al. 1 published a phase 3 trial on the effects of olezarsen, a third-generation antisense oligonucleotide that blocks apoC-III mRNA, on triglycerides and risk of acute pancreatitis. Competing Interests: Declaration of interests P.V. received honoraria for presentations and advisory boards from AMGEN, Sanofi, Servier, Novartis, MSD, Alexion, Sobi, Akcea, and PTB. P.V. also received research grants from Ferrer and Sobi and technology transfer contracts with Lipigon Pharmaceuticals and Capenergy Medical. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Apolipoprotein C-III) 0 (Oligonucleotides) 0 (Triglycerides) 0 (ISIS 304801) 0 (Oligonucleotides, Antisense) 0 (BMS201038) 0 (Benzimidazoles) |
| SCR Disease Name: | Familial hyperchylomicronemia syndrome |
| تواريخ الأحداث: | Date Created: 20240615 Date Completed: 20240615 Latest Revision: 20240628 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.medj.2024.05.004 |
| PMID: | 38878767 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2666-6340 |
|---|---|
| DOI: | 10.1016/j.medj.2024.05.004 |